{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:06Z","timestamp":1783161426145,"version":"3.54.6"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pacritinib, a selective Janus kinase (JAK) inhibitor, is approved for the treatment of myelofibrosis in adults with severe thrombocytopenia. However, its safety profile in real-world populations remains unclear. The aim of study is provided a comprehensive profile of pacritinib's safety by evaluating the adverse events (AEs) using a real-world pharmacovigilance database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the FDA Adverse Event Reporting System (FAERS) database, spanning from the first quarter of 2022 to the second quarter of 2024, served as the basis for this analysis. To identify potential AE risk signals, several disproportionality analysis methods were applied, including the reporting odds ratio, the proportional reporting ratio, the multi-item gamma Poisson shrinker, and the Bayesian confidence propagation neural network.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 4,304,335 AE reports were collected from the FAERS, with 1,940 reports identifying pacritinib as the primary suspect drug. Significant disproportionality was observed in the following system organ classes: gastrointestinal disorders, investigations, and surgical and medical procedures. Common preferred terms were identified, including diarrhea, fatigue, death, nausea, platelet count decreased, and hemoglobin decreased. Notably, 26 off\u00ad-label AEs were also identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study would provide valuable insights for the post-marketing safety surveillance and assessment of pacritinib, and guide its clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1618267","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:10:02Z","timestamp":1753708202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.3389","volume":"15","author":[{"given":"Huiling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.007","article-title":"State-of-the-art review on myelofibrosis therapies","volume":"22","author":"Wang","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2020.08.018","article-title":"Myelofibrosis: A review","volume":"42","author":"Genthon","year":"2021","journal-title":"Rev Med Interne"},{"key":"B3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.08.006","article-title":"Mechanisms of mutations in myeloproliferative neoplasms","volume":"22","author":"Levine","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.06.012","article-title":"Consistency of spleen and symptom reduction regardless of cytopenia in patients with myelofibrosis treated with pacritinib","volume":"24","author":"Gagelmann","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27529","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"B12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540542","article-title":"Real-world disproportionality analysis of the food and drug administration adverse event reporting system database for asciminib","volume":"102","author":"Liu","year":"2024","journal-title":"Oncology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A review of statistical methods for safety surveillance","volume":"48","author":"Huang","year":"2014","journal-title":"Ther Innov Regul Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel adverse events of iloperidone: A disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database","volume":"14","author":"Subeesh","year":"2019","journal-title":"Curr Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"JAKs in pathology: role of Janus kinases in hematopoietic Malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382872","article-title":"Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives","volume":"14","author":"Breccia","year":"2024","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid Malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2217\/fon-2017-0494","article-title":"Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia","volume":"14","author":"Diaz","year":"2018","journal-title":"Future Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1294668","article-title":"Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid Malignancies: a systemic analysis of clinical trials","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1500456","article-title":"Pacritinib to treat myelofibrosis patients with thrombocytopenia","volume":"11","author":"Tremblay","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/jep.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.591","article-title":"Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis","volume":"3","author":"Pemmaraju","year":"2022","journal-title":"EJHaem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2174\/1871520623666230320120915","article-title":"First approval of pacritinib as a selective janus associated kinase-2 inhibitor for the treatment of patients with myelofibrosis","volume":"23","author":"De","year":"2023","journal-title":"Anticancer Agents Med Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1872312809666150119105250","article-title":"Metabolism and disposition of pacritinib (SB1518), an orally active janus kinase 2 inhibitor in preclinical species and humans","volume":"9","author":"Jayaraman","year":"2015","journal-title":"Drug Metab Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1618267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:10:03Z","timestamp":1753708203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1618267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":35,"alternative-id":["10.3389\/fonc.2025.1618267"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1618267","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"1618267"}}